If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Worldwide Countries outside of the United States and Canada.įorward-Looking Statement Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA.We are known as Merck & Co., Inc., Rahway, New Jersey, USA in the United States, Canada & Puerto Rico. 7, 13–14 (2008).We are one company, but we operate under two different corporate brand names. The use of electronic data capture tools in clinical trials: web-survey of 259 Canadian trials. The Pink Sheet 73 < (11 April 2011).Įl Emam, K. Disclosing drug discovery failures would aid regulatory science, FDA's Hamburg says. Publication of clinical trials supporting successful new drug applications: a literature analysis. The Wealth of Networks (Yale University Press, 2006). Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. The BATTLE Trial: personalizing therapy for lung cancer. Biomarker-led adaptive trial blazes a trail in breast cancer. Cutting Edge < (15 July 2011).Īllison, M. Clinical Operations: Benchmarking per-patient costs, staffing and adaptive design. Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. Health and Human Services September, 2001). The Globalization of Clinical Trials: a Growing Challenge in Protecting Human Subjects (US Dept. The Economic Times < (15 July 2008).ĭHHS Office of the Inspector General. Clinical trial biz likely to be $546 mn by 2011: Assocham. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. Measuring the incidence, causes, and repercussions of protocol amendments. Drugs, money and glory: is cancer beating cardiovascular disease? < (11 August 2011). Trial watch: phase III and submission failures: 2007–2010. Drug R&D spending fell in 2010, and heading lower. The errors have been corrected in the HTML and PDF versions of the article. In addition, it should have been noted that Eric Westin, who was interviewed while senior director of Lilly Oncology, had left the company. If they delay in responding, a reminder can be sent.” And for space reasons, other text relating to Recruit, “The tool is integrated with Pfizer’s volunteer database and allows immediate text message-based communication and assessment of a subject’s suitability within 5-10 min” and “It can also be used to send protocol-specific messages to patients already enrolled in trials” was deleted. 3) via their mobile phones or home computers. Instead of “new technology to recruit patients faster and in a more standardized fashion, ”the text now reads, “new technology to allow home-based clinical trial data reporting.” Instead of “‘Recruit’ text messaging technology in a pilot study” for Detrol, the text now reads, “‘eDiary’ tool in a Phase 4 trial, called Research on Electronic Monitoring of OAB Treatment Experience.” Additional explanation has been added, including “Patients can respond to simple questionnaires (Fig. The text references to Recruit have been replaced with an explanation of eDiary. The Recruit technology is being used in other studies. In the version of the article originally published, the ExoInTouch product being used by Pfizer in its virtual trial for overactive bladder (OAB) is eDiary, not Recruit, which allows patients to report through mobile phone or internet portals.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |